MedTrace Logo

The Effect of Memantine on Brain Structure and Chemistry in Alzheimer's Disease Patients

NCT00255086 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 17

Last updated 2017-04-07

Study results available
· View outcomes & findings →

Summary

The aim of the proposed study is to determine if the NMDA receptor antagonist memantine has a neuroprotective effect on magnetic resonance spectroscopic imaging (MRS) measures of brain NAA and magnetic resonance imaging (MRI) volumetric measures of hippocampal volume. In secondary analyses, we will determine if measures of clinical stabilization produced by memantine in the treatment of Alzheimer's disease (AD) parallels stabilization of MRS measures of brain NAA and MRI volumetric measures of hippocampal volume.

Conditions

  • Alzheimer Disease

Interventions

DRUG

Memantine

10mg Memantine

DRUG

Placebo pill

10mg placebo pill

Sponsors & Collaborators

  • Palo Alto Veterans Institute for Research

    collaborator OTHER

  • Forest Laboratories

    collaborator INDUSTRY

  • Stanford University

    lead OTHER

Principal Investigators

  • J. Wesson Ashford Jr., MD, PhD · Stanford University

  • Jerome A Yesavage · Stanford University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Max Age
95 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-05-31
Primary Completion
2009-06-30
Completion
2010-02-28

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00255086 on ClinicalTrials.gov